Bloomage Biotech H1 2026 Revenue Falls 22.32%, Net Profit Drops 30.82%
Bloomage Biotechnology disclosed its 2026 interim report, showing revenue of RMB 1.756 billion for the first half, down 22.32% year on year. Net profit attributable to shareholders was RMB 153 million, a decline of 30.82%. Basic earnings per share stood at RMB 0.32. Revenue from its skin science innovation transformation business also declined during the period.
Bloomage Biotechnology has released its interim report for the first half of 2026. The report shows that during the period, the company generated operating revenue of RMB 1.756 billion, a year-on-year decrease of 22.32%. Net profit attributable to shareholders of the listed company was RMB 153 million, down 30.82% from the same period last year. Basic earnings per share amounted to RMB 0.32. During the reporting period, revenue from the company's skin science innovation transformation business declined year on year.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is negative for Cosmetics, with intensity 60/100 and 70% confidence over a short term horizon.
Cosmetics
- Direction
- negative
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Short term
Biotechnology
- Direction
- negative
- Intensity
- 50
- Confidence
- 60%
- Horizon
- Short term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.